CEGIR’s Glenn Furuta Receives NASPGHAN 2021 Harry Shwachman Award Dakota Campbell Tue, 12/14/2021 - 10:54
Headshot of Glenn Furuta, MD

Glenn Furuta, MD, has received the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2021 Harry Shwachman Award. Furuta was recognized during the 2021 NASPGHAN Annual Meeting on Monday, December 13.

Dr. Rothenberg received the Paul Ehrlich Lectureship Award Anonymous (not verified) Thu, 02/28/2019 - 09:33
Dr. Rothenberg

Dr. Rothenberg, the Principal Investigator for CEGIR, has been awarded the highest honor bestowed by the International Eosinophil Society for his major contributions to the advancement of our understanding of the eosinophil.

Precision Medicine approach to Nephrotic Syndrome Anonymous (not verified) Wed, 02/27/2019 - 15:05

NEPTUNE has embraced the concept of Precision Medicine proposed by the Institute of Medicine in 2011. The Precision Medicine strategy proposes the development of new disease definitions generated by a multilayered analysis of the disease course while patients receive their usual clinical care in observational studies.

Primary Immune Deficiency Treatment Consortium (PIDTC) Anonymous (not verified) Wed, 02/27/2019 - 14:46
The PIDTC conducts multi-center studies of primary immune deficiency (PID) diseases and aims to expand the understanding and improve treatments and outcomes for patients with rare PIDs.
CReATe Consortium initiates biomarker validation study in preparation for clinical trials Anonymous (not verified) Wed, 02/27/2019 - 14:34

Through a recently awarded Clinical Trial Readiness grant from NINDS, CReATe investigators are now tapping into the invaluable resource that is the CReATe Biorepository in an effort to clinically validate leading biological fluid-based biomarker candidates to aid the design and implementation of future clinical trials.

Brittle Bone Disorders Consortium pioneers Osteogenesis Imperfecta research and treatment Anonymous (not verified) Wed, 02/27/2019 - 14:07

Through research, the BBDC is discovering new biomarkers of the disease that will lead to a deeper understanding of underlying pathophysiology of OI as well as assessing response to therapies